个人介绍 学术任职 学术论着 专家风采
张宇航，男，1994年生。本-硕-博均就读于首都医科大学，获药理学博士学位，曾赴加拿大麦吉尔大学联合培养。timi天美传孟若羽副研究员，助理教授，硕士生导师。主要研究方向为：代谢性疾病创新药的肠道微生物组学图谱研究、阴道菌群移植痴惭罢技术改善剖宫产婴儿神经发育的分子机制研究。主持国家自然科学基金青年科学基金项目、北京市自然科学基金面上项目等纵向课题9项。部分学术成果作为受试口服药临床疗效替代终点的重要微生物指标，为肠道微生态监管科学的发展提供重要数据基础。
张宇航博士在2022年入选北京市科协青年人才托举工程，2024年入选中国科协青年人才托举工程。担任中国药学会药物临床评价研究专业委员会委员、中国药理学会临床药理委员会委员、《中国临床药理学杂志》青年编委等。
(1) Yu-Hang Zhang#, Ran Xie#, Chen-Shu Dai, Hong-Wei Gao, Gan Zhou, Tian-Tian Qi, Wen-Yu Wang, Hua Wang*, Yi-Min Cui*. Thyroid hormone receptor-beta agonist HSK31679 alleviates MASLD by modulating gut microbial sphingolipids. Journal of Hepatology, 2025 Feb;82(2):189-20 2. 2024 IF = 26.800.
(2) Yu-Hang Zhang#, Dong-Dong Luo#, Sheng-Biao Wan, Xian-Jun Qu*; Mincle inhibitors potently reverse 5-FU resistance by downregulating DPD expression in colorectal cancer, Pharmacological Research, 2020, 155: 104717. 2020 IF = 10.334.
(3) Yu-Hang Zhang, Wen-Na Shi, Shu-Hua Wu, Rong-Rong Miao, Shi-Yue Sun, Dong-Dong Luo, Sheng-Biao Wan, Zhi-Kun Guo, Wen-Yu Wang, Xin-Feng Yu, Shu-Xiang Cui*, Xian-Jun Qu*; SphK2 confers 5-fluorouracil resistance to colorectal cancer via upregulating H3K56ac-mediated DPD expression, Oncogene, 2020, 39: 5214-5227. 2020 IF = 9.867.
(4) Yu-Hang Zhang, Wen-Yu Wang, Yi-Min Cui*; Gut microbiome metabolism drives the resolution of patients with COVID-19, Gastroenterology, 2022, 163(1):336-337. 2022 IF = 32.682.
(5) Yu-Hang Zhang, Shu-Xiang Cui, Sheng-Biao Wan, Shu-Hua Wu, Xian-Jun Qu*; Increased S1P induces Mincle internalization to blunt the sensitivity of CRC to 5-fluorouracil via promoting intracellular uracil generation, Acta Pharmacologica Sinica, 2021, 42:460-469. 2021 IF = 6.150.
(6) Dong-Dong Luo#, Yu-hang Zhang#, Shuang Yang#, Xiao-Chen Tian, Yan Lv, Zhi-Kun Guo, Wen-Yu Wang, Shu-Xiang Cui, Xian-Jun Qu*, Sheng-Biao Wan*; Design, synthesis and biological evaluation of Mincle antagonists as potent 5-FU resistance reversal agents for the treatment of colorectal cancer, European Journal of Medicinal Chemistry, 2021, 225: 113775. 2021 IF = 6.514.
(7) Yu-Hang Zhang, Wen-Yu Wang, Xiao-Cong Pang, Zhi Wang, Cheng-Zhuo Wang, Hang Zhou, Bo Zheng*, Yi-Min Cui*; Thymosin-α1 binds with ACE and downregulates the expression of ACE2 in human respiratory epithelia, Frontiers in Bioscience-Landmark, 2022, 27(2),048. 2022 IF = 4.009.
(8) Yu-Hang Zhang, Xian-Jun Qu*. An oasis in the desert of cancer chemotherapeutic resistance: The enlightenment from reciprocal crosstalk between signaling pathways of UPR and autophagy in cancers, Biomedicine & Pharmacotherapy. 2017, 92:972-981. 2017 IF = 6.529.
(9)&苍产蝉辫;曲显俊，张宇航，崔淑香。201911341629.1：一种治疗消化道癌症的药物组合物，国家知识产权局。
(10) 曲显俊，万升标，张宇航，崔淑香。202010051408.7：DPD抑制剂及其制备方法、药物组合物和用途，国家知识产权局。
(11) 张宇航、崔一民、郑波、李耘、庞晓丛、张峻岭、王雯玉、王智、崔兰卿。202111497641.9：拟杆菌属肠道菌及其代谢相关物质在制备逆转THR-β激动剂耐药性的药物中的用途，国家知识产权局。
(12) 崔一民、张宇航、齐田田、戴晨曙。202410212000.1：甲状腺激素β受体激动剂在制备改善肠道菌群药物中的应用，国家知识产权局。
(13) 崔一民、张宇航、齐田田、戴晨曙、王雯玉、潘森涛。202411195150.2：葡萄糖神经酰胺合酶抑制剂在制备预防和/治疗代谢应激性肝脏损伤相关疾病产物中的应用，国家知识产权局。
(14) timi天美传孟若羽、张宇航、王雯玉、崔一民。软著登字第9345465号：菌群代谢调控脂肪个体化用药系统v1.0，国家版权局。
北京市西城区西什库大街8号
100034
83572211